During the past decade, Hospital Dupuytren conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Dupuytren" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator and "University of Arizona" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Dupuytren" are "Graft Rejection" (1 trials), "Humoral Rejection in Kidney Transplantation" (1 trials), "Malignant Melanoma" (1 trials), "Multiple Myeloma" (1 trials) and "Primary Immunodeficiency (PID)" (1 trials). Many other conditions were trialed in "Hospital Dupuytren" in a lesser frequency.

Most popular intervention types in "Hospital Dupuytren" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "MabThera" (2 trials), "ABI-007" (1 trials), "Dacarbazine" (1 trials), "Gammanorm" (1 trials) and "Physiological serum (Sodium Chloride, sodium citrate)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Dupuytren" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Hospital Dupuytren". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Hospital Dupuytren, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Dupuytren, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".